A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...
One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many ...
Clinical Trials Arena on MSN20h
Moleculin Biotech begins dosing subjects in combination therapy trial for AMLUS-based pharmaceutical company Moleculin Biotech has begun dosing subjects in its Phase III MIRACLE trial of Annamycin with ...
The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...
A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback